- Market Capitalization, $K 2,154,190
- Shares Outstanding, K 19,664
- Annual Sales, $ 251,450 K
- Annual Income, $ 143,320 K
- 60-Month Beta 1.40
- Price/Sales 8.59
- Price/Cash Flow 11.72
- Price/Book 2.00
|Period||Period Low||Period High||Performance|
| || |
-3.83 (-3.38%)since 05/24/19
| || |
-13.58 (-11.03%)since 03/25/19
| || |
-82.65 (-43.00%)since 06/25/18
Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840,...
AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.
Mallinckrodt (MNK) earnings and sales surpass estimates in the first quarter, which led to an increase in annual guidance.
Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin...
Ligand Pharm (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $115.25 to a high of $127.29. Yesterday, the shares fell 9.2%, which took the trading range below the 3-day low of $123.14...
Ligand (LGND) delivered earnings and revenue surprises of -95.92% and 13.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Thursday reported first-quarter earnings of $666.3 million.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2019 and provided an operating forecast and program updates. Ligand...